Vitamin D and Multiple Sclerosis — Does Supplementation Reduce Relapse Risk?

Multiple sclerosis (MS) is a chronic autoimmune disease in which the immune system mistakenly attacks the myelin sheath of nerve fibers in the brain and spinal cord. Damage to myelin disrupts the transmission of nerve signals, producing highly varied symptoms — from sensory and visual disturbances, through muscle weakness, to problems with balance and cognitive function. In most patients the disease follows a relapsing-remitting course: periods of worsening symptoms (relapses) alternate with periods of partial or full remission, though over time some patients transition to a secondary progressive form.

Vitamin D didn't end up at the center of MS research by accident. For decades, epidemiology has observed a clear geographic gradient: the prevalence and incidence of MS increase with distance from the equator, that is, in regions with less annual UVB exposure and lower skin synthesis of vitamin D. Migration studies confirm the same pattern — people who move at a young age from low-risk to high-risk regions (and vice versa) partly take on the risk characteristic of their new place of residence. This is one of the most reproducible observational patterns in MS epidemiology, and the main reason vitamin D became one of the most intensively studied environmental factors in this disease.

A team led by Hanaei and colleagues gathered and analyzed all available randomized trials assessing the effect of vitamin D supplementation on two hard, clinically meaningful endpoints in patients with already-diagnosed MS: relapse frequency and the score on the EDSS (Expanded Disability Status Scale) — the standard, widely used scale for assessing the degree of neurological disability in MS, where a higher score means greater functional impairment.

In other words: this isn't a study that confirms a benefit and merely refines its size. The result is outright negative in a statistical sense — the confidence intervals for both comparisons (placebo, and high vs. low dose) are wide and encompass the possibility of both a small benefit and a small harm, but they don't allow any reliable effect to be established in either direction.

This is an apparent contradiction — if vitamin D deficiency correlates so clearly with MS risk in population studies, why doesn't giving it to people who already have the disease change its course in this meta-analysis? Several explanations are plausible simultaneously, rather than mutually exclusive.

It's also worth noting what this meta-analysis didn't assess at all: it didn't examine whether maintaining a normal vitamin D level in healthy people reduces the risk of developing MS in the first place (that's a separate, preventive question requiring a different type of study with a much longer time horizon). Nor did it assess vitamin D's general effects on bone health, the immune system, or other areas that remain well documented independently of the MS context — we cover this more broadly in our knowledge-base entry on vitamin D3.

It's also worth remembering that vitamin D remains important for patients with MS for entirely different, well-documented reasons unrelated to the course of the neurological disease itself: reduced mobility, limited sun exposure (particularly with advanced disability), and the use of certain medications, including glucocorticoids for treating relapses, can themselves increase the risk of vitamin D deficiency and the associated weakening of bone density. Checking 25(OH)D levels and correcting any deficiency therefore remains justified as part of general patient care — just not as a strategy for treating MS itself.

It's rare to find a topic where the gap between a strong, reproducible observational association and the results of interventional trials is as stark as it is with vitamin D and multiple sclerosis. It's a good illustration of a broader principle in evidence-based medicine: correlation in population data, even when very strong and reproducible, doesn't exempt an intervention from being tested in a randomized trial before it starts being recommended as part of treatment.

This doesn't mean the topic is closed — the 2021 meta-analysis covered a relatively small number of patients and studies from before 2018, and the question of whether there's a subgroup of patients or a specific dosing regimen at which an effect might emerge remains open. Until such data exist, vitamin D in the context of MS remains justified for bone health and overall bodily function — not as a tool for controlling the disease itself.